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ARationale & Objective: Diabetic patients with
declining kidney function are at heightened risk
for hypoglycemia. We sought to determine
whether hypoglycemia-related hospitalizations in
the interval before dialysis therapy initiation are
associated with post–end-stage renal disease
(ESRD) mortality among incident patients with
ESRD with diabetes.
Study Design: Observational cohort study.
Setting & Participants: US veterans from the
national Veterans Affairs database with diabetes
and chronic kidney disease transitioning to
dialysis therapy from October 2007 to
September 2011.
Exposure: Hypoglycemia-related hospitalizations
during the pre-ESRD period and antidiabetic
medication regimens.
Outcome: The outcome of post-ESRD all-cause
mortality was evaluated relative to pre-ESRD
hypoglycemia. The outcome of pre-ESRD
hypoglycemia-related hospitalization was
evaluated relative to antidiabetic medication
regimens.
Analytic Approach: We examined whether
the occurrence and frequency of pre-ESRD
hypoglycemia-related hospitalizations are
associated with post-ESRD mortality using Cox
regression models adjusted for case-mix
covariates. In a subcohort of patients prescribed
0 to 2 oral antidiabetic drugs and/or insulin, we
examined the 12 most commonly prescribedJKD Vol 72 | Iss 5 | November 2018antidiabetic medication regimens and risk for
pre-ESRD hypoglycemia-related hospitalization
using logistic regression models adjusted for
case-mix covariates.
Results: Among30,156patientswhomet eligibility
criteria, theoccurrenceof pre-ESRDhypoglycemia-
related hospitalization(s) was associated with
higher post-ESRD mortality risk: adjusted HR
(aHR), 1.25; 95% CI, 1.17-1.34 (reference group:
no hypoglycemia hospitalization). Increasing
frequency of hypoglycemia-related hospitalizations
was independently associated with incrementally
higher mortality risk: aHRs of 1.21 (95% CI,
1.12-1.30), 1.47 (95% CI, 1.19-1.82), and
2.07 (95% CI, 1.46-2.95) for 1, 2, and 3
or more hypoglycemia-related hospitalizations,
respectively (reference group: no hypoglycemia
hospitalization). Compared with patients who were
prescribed neither oral antidiabetic drugs nor
insulin, medication regimens that included
sulfonylureas and/or insulin were associated with
higher risk for hypoglycemia.
Limitations: Residual confounding cannot be
excluded.
Conclusions: Among incident patients with
ESRD with diabetes, a dose-dependent
relationship between frequency of pre-ESRD
hypoglycemia-related hospitalizations and post-
ESRD mortality was observed. Further study of
diabetic management strategies that prevent
hypoglycemia as patients with chronic kidney
disease transition to ESRD are warranted.Chronic kidney disease (CKD) is one of the most prev-alent complications of diabetes mellitus, affecting 30%
to 40% of patients with type 1 and 2 diabetes.1 Diabetic
kidney disease accounts for 44% of incident end-stage renal
disease (ESRD) cases in the United States, and the annual
mortality rate of diabetic patients with ESRD exceeds those
with other ESRD causes.2 Hence, there is compelling need to
identify modifiable risk factors for the exceedingly high
death risk of the diabetic ESRD population, particularly in the
early phases of transitioning from non–dialysis-dependent
(NDD) CKD to ESRD treated bymaintenance dialysis, when a
mortality peak is observed.2-4
Optimal glycemic control is an ongoing area of un-
certainty in the management of diabetic patients with
CKD.5 Although early trials showed that intensive glycemic
control lowers the risk for microvascular complications
in diabetic patients with minimal end-organ damage,6,7contemporary trials have shown lack of benefit and
adverse cardiovascular outcomes among patients with
long-standing type 2 diabetes with underlying cardiovas-
cular risk, individuals who are akin to diabetic patients
with kidney disease.8-11 Furthermore, the mentioned trials
have shown that hypoglycemia may be a trade-off of the
benefits of intensive glycemic control.8,9,11,12 Diabetic
patients with NDD-CKD progressing to maintenance dial-
ysis therapy may be vulnerable to hypoglycemia due to
impaired renal gluconeogenesis, longer insulin half-life,
reduced antidiabetic medication metabolism and clear-
ance, and co-existing comorbid conditions (eg, malnutri-
tion and gastroparesis).5,13,14 Observational data suggest
that more than one-third of incident diabetic hemodialysis
patients may experience spontaneous normalization of
hyperglycemia and frequent hypoglycemic events neces-
sitating discontinuation of antidiabetic medications.5,15701
Original InvestigationIn the general population, hypoglycemia is associated
with heightened risk for hospitalization,16,17 mortal-
ity,12,18,19 and cost burden.20 However, there has been
sparse examination of risk factors and sequelae of hypo-
glycemia in diabetic patients with kidney disease, partic-
ularly among those progressing to ESRD. Prior studies are
limited by lack of antidiabetic medication data21 or re-
striction to study populations at the extremes of CKD. With
respect to the latter, these studies have exclusively focused
on NDD-CKD21-23 versus maintenance dialysis patients,24
and it is unknown whether repeated hypoglycemic
events more than 1 to 2 years before transitioning to ESRD
have long-term sequelae during ESRD in patients who
survive to dialysis therapy.
A substantial impediment to this end has been the
paucity of pre-ESRD transition data across large post-ESRD
databases.3 Thus, through linkage of pre-ESRD data from
the national Veterans Affairs (VA) database with post-ESRD
registries (US Renal Data System [USRDS]), we sought to
examine the relationship between pre-ESRD hypoglycemia
events during the predialysis transition period with post-
ESRD mortality among US veterans with diabetes. We
also investigated clinical characteristics associated with risk
for hypoglycemia in the pre-ESRD transition period.Methods
Source Cohort
We conducted a historical cohort study with longitudinal
data from the Transition of Care in CKD (TC-CKD) study, a
retrospective cohort study examining US veterans tran-
sitioning to ESRD from October 1, 2007, to September 30,
2011.3,25-28 Our source population consisted of 52,172
patients who were identified from the national VA database
and linked to the USRDS registry. Patients were included
provided that they were 18 years or older at the time of
entry into the VA health care system, had a history of
diabetes ascertained by International Classification of Diseases,
Ninth Revision (ICD-9) codes (249.xx, 250.xx, 357.2,
362.0x, and 366.41) before dialysis therapy initiation
and/or cause of ESRD due to diabetes, had no missing data
for core variables needed to calculate estimated glomerular
filtration rate (eGFR), and initiated dialysis therapy before
study entry or after exiting the study (Fig S1).
Patients were categorized into various analytic cohorts
according to their time of entry into the VA health care
system, which defined their pre-ESRD observation intervals
before transitioning to dialysis therapy: more than 6- to
12-month, more than 1- to 2-year, and more than 2- to 5-
year prelude periods. Given that a core objective of the
TC-CKD study is to determine the impact of pre-ESRD
comorbid conditions on post-ESRD outcomes, we a pri-
ori defined the more than 1- to 2-year prelude period as
our primary exposure window during which potential
interventions informed by the present study can have
greater impact on post-ESRD outcomes (ie, modification of
comorbid conditions/events in earlier stages of CKD may702have greater impact on outcomes as compared with later
stages). The study was approved by the institutional review
boards of the University of California Irvine, Tibor Rubin
VA, and Memphis VA. The study was exempt from
informed written consent due to its nonintrusive nature
and anonymity of patients.
Exposure Ascertainment
Given that hypoglycemia events ascertained by blood
glucose levels may not be captured in the VA database (ie,
low capillary blood glucose levels observed in the field),
we focused on hypoglycemia events requiring medical
attention by identifying hypoglycemia-related hospitali-
zation(s) ascertained by ICD-9 codes using VA, Centers for
Medicare & Medicaid Services (CMS), and USRDS sources
(251.0-251.3, 962.3, 995.23, 996.57, E9323; and
250.80-250.83 but without 259.8, 272.7, 681.xx,
682.xx, 686.9x, 707.1-707.9, 709.3, 730-730.2, or
731.8).29-32 In coprimary analyses, we first examined the
association of any occurrence of hypoglycemia-related
hospitalization(s) (presence vs absence) with mortality
risk. We then examined the association between the fre-
quency of hypoglycemia-related hospitalization(s) with
mortality.
Sociodemographic, Comorbidity, Medication, and
Laboratory Data
Data from VA and USRDS Patient and Medical Evidence files
were used to determine patients’ sociodemographic infor-
mation at the time of dialysis therapy initiation. Cause of
ESRD and dialysis modality information were obtained from
USRDS sources. Comorbid condition data were extracted
from the VA Inpatient and Outpatient Medical SAS data
sets33 and CMS data sets using ICD-9 diagnostic/procedure
and Current Procedural Terminology codes.34 Charlson Comor-
bidity Index (CCI) scores were estimated using the Deyo
modification for administrative data sets without including
kidney disease.35 Medication data were obtained from CMS
Part D and VA pharmacy dispensation records.36 Hemo-
globin A1c (HbA1c), random glucose, and other laboratory
data except serum creatinine were obtained from the VA
Decision Support System-National Data Extracts Laboratory
Results files.37 VA Corporate Data Warehouse LabChem data
files were used to extract serum creatinine data.38 The CKD-
EPI (CKD Epidemiology Collaboration) creatinine equation
was used to calculate eGFR.39
Outcome Ascertainment
Our outcome of interest was all-cause mortality. Patients
were censored at kidney transplantation, loss to follow-up,
or the last date of available follow-up data (December 27,
2012), whichever occurred first. The at-risk period began
the day after dialysis therapy initiation (ie, following the
exposure window) and concluded upon experiencing the
outcome of interest or a censoring event. All-cause mor-
tality, censoring events, and associated dates were obtained
from VA, CMS, and USRDS sources.AJKD Vol 72 | Iss 5 | November 2018
Original InvestigationStatistical Analysis
We conducted logistic regression analyses examining the
association of modifiable and nonmodifiable sociodemo-
graphic, comorbidity, dialysis treatment, laboratory, and
antidiabetic medication characteristics with likelihood of
experiencing hypoglycemia-related hospitalization(s)
during the more than 1- to 2-year prelude period. In a
subcohort of patients prescribed 0 to 2 oral antidiabetic
drugs and/or insulin, we also examined the 12
most commonly prescribed antidiabetic medication
regimens and risk for pre-ESRD hypoglycemia-related
hospitalization(s).
We then estimated the association of any occurrence
(separately) and frequency of hypoglycemia-related hos-
pitalization(s) with mortality using Cox models. Logistic
regression and Cox models were conducted using 5 hi-
erarchical levels of covariate adjustment: (1) minimally
adjusted model: adjusted for patient’s calendar quarter of
dialysis therapy initiation to account for secular changes in
care over time; (2) case-mix model: adjusted for cova-
riates in model 1, plus age at dialysis therapy initiation,
sex, race, and ethnicity; (3) expanded case-mix model:
adjusted for covariates in model 2, plus cause of ESRD,
initial dialysis modality, residential region, congestive
heart failure (CHF), cerebrovascular disease, and CCI
score; (4) expanded case-mix plus laboratory model:
adjusted for covariates in model 3, plus HbA1c, serum
albumin, eGFR averaged over the prelude period (ie,
proxy of residual kidney function), and last eGFR obtained
before dialysis therapy initiation (ie, proxy of dialysis
practice patterns); and (5) expanded case-mix plus labo-
ratory plus medication model: adjusted for covariates in
model 4 plus insulin and oral antidiabetic drug use during
the exposure period.
We a priori defined the case-mix model as our preferred
model, which included core sociodemographic measures
and other confounders of the association between
hypoglycemia-related hospitalizations and mortality.
Although there were no missing data for covariates in case-
mix models, there were varying degrees of missing data
for covariates in expanded case-mix, expanded case-mix
plus laboratory, and expanded case-mix plus laboratory
plus medication models, including cause of ESRD (4.8%),
modality (10.9%), residential region (3.9%), HbA1c level
(42.6%), serum albumin level (41.7%), eGFR averaged
over the prelude period (37.8%), and last eGFR obtained
before dialysis therapy initiation (37.8%; proportions
shown represent data from the more than 1- to 2-year
prelude cohort). Hence, further adjustment for potential
confounders in these latter models (which have the
potential for inherent selection bias due to missing data)
were conducted as sensitivity analyses. Models incremen-
tally adjusted for pre-ESRD eGFR slope and proxies
of diabetes severity (eg, number of oral antidiabetic
drugs and insulin type) were also examined as sensitivity
analyses.AJKD Vol 72 | Iss 5 | November 2018To address missing covariate data, we implemented
multiple imputation, which generates complete data sets
(ie, replaces missing values in the data set) by borrowing
information from other covariates and accounts for un-
certainty associated with the estimation of missing
values when estimating the regression parameters, lo-
gistic regression parameter, and discriminant function
method parameter, according to variable type and using
the PROC MI procedure in SAS (SAS Institute Inc).40 We
included the following variables in the imputation
model using 7 imputed data sets: age, sex, race,
ethnicity, residential region, CCI score, CHF, cerebro-
vascular disease, HbA1c level, serum albumin level,
eGFR, insulin, and oral antidiabetic drug use. The PROC
MIANALYZE procedure was then used to combine results
across imputations.
We also conducted subgroup analyses of any occurrence
of hypoglycemia-related hospitalization(s) and mortality
across clinically relevant subgroups. Proportional hazards
assumptions were confirmed using graphical analysis.
Analyses and figures were generated using SAS, version
9.4; Stata, version 13.1 (Stata Corp), and SigmaPlot,
version 12.5 (Systat Software).Results
Study Population
Among 30,156 patients who met eligibility criteria for the
more than 1- to 2- year prelude period (Fig S1), 5.9%
experienced 1 or more hypoglycemia-related hospitaliza-
tion(s) before dialysis therapy initiation, with 94.1%,
5.1%, 0.6%, and 0.2% experiencing 0, 1, 2, and 3 or more
hypoglycemia-related hospitalizations (Table S1). Among
these patients, 0.1%, 98.3%, and 1.6% had type 1, type 2,
and unknown diabetes type, respectively, and the overall
mean and median eGFR slope was −10.5 ± 8.92 (standard
deviation) and −8.2 (quartile 1 [Q1]-Q3, −13.0 to −5.1)
mL/min/1.73 m2 per year, respectively. Patients with the
presence of any hypoglycemia-related hospitalization(s)
tended to be younger, were less likely to be white, were
more likely to be receiving in-center hemodialysis, had a
higher CCI score and were more likely to have CHF or
cerebrovascular disease, had higher HbA1c and prelude-
averaged eGFR and lower serum albumin values, and
were more likely to be using insulin (including rapid-,
short-, intermediate-, and long-acting types) and oral
antidiabetic drugs (including sulfonylureas, thiazolidine-
diones, and metformin) compared with those with
absence of hypoglycemia-related hospitalization(s)
(Table 1).
Clinical Characteristics and Hypoglycemia-Related
Hospitalization Risk
In case-mix logistic regression analyses, patients of
Hispanic ethnicity, with CHF or cerebrovascular disease,
with higher HbA1c and prelude-averaged eGFR values,703
Table 1. Baseline Characteristics Among Patients According to Presence Versus Absence of Hypoglycemia-Related Hospitalization
in the More Than 1- to 2-Year Prelude Period
Overall
(N = 30,156)
Hospitalization
P
Presence
(n = 1,767; 5.9%)
Absence
(n = 28,389; 94.1%)
Age at dialysis initiation, y 72 ± 11 71 ± 10 72 ± 11 0.001
Female sex 5% 5% 5% 0.6
White race 74% 66% 74% <0.001
Hispanic ethnicity 7% 8% 7% 0.2
Cause of ESRD <0.001
Diabetes 60% 71% 59%
Hypertension 22% 18% 23%
Glomerulonephritis 3% <1% 3%
Cystic kidney disease <1% <1% <1%
Other urologic disorder <1% <1% <1%
Other cause 9% 6% 9%
Unknown/missing 5% 4% 5%
Modality <0.001
In-center HD 84% 87% 84%
Home HD/PD 5% 3% 5%
Unknown 11% 10% 11%
Residential region 0.4
Northeast 18% 18% 18%
Midwest 23% 22% 23%
South 42% 43% 42%
West 18% 17% 18%
Comorbid conditions
Charlson Comorbidity Index score 6 ± 3 7 ± 3 6 ± 3 <0.001
Congestive heart failure 65% 75% 64% <0.001
Cerebrovascular disease 35% 41% 35% <0.001
Laboratory tests
Hemoglobin A1c, % 6.9% [6.2%-7.9%] 7.2% [6.3%-8.3%] 6.9% [6.2%-7.8%] <0.001
Serum albumin, g/dL 3.6 [3.2-3.9] 3.4 [3.0-3.8] 3.6 [3.2-3.9] <0.001
eGFR averaged over the prelude
period, mL/min/1.73 m2
21 [16-31] 23 [17-33] 21 [16-30] <0.001
eGFR at dialysis initiation, mL/min/
1.73 m2
14 [10-22] 14 [10-23] 14 [10-22] 0.4
Medications
Insulin 45% 60% 44% <0.001
Oral antidiabetic medications 48% 61% 48% <0.001
Alpha-glucosidase inhibitor 2% 3% 2% <0.001
Sulfonylurea 39% 49% 39% <0.001
Thiazolidinedione 17% 22% 17% <0.001
Metformin 18% 25% 18% <0.001
DPP-4 inhibitor 1% 1% 1% 0.9
Meglitinide 1% 2% 1% <0.001
Rapid-acting insulin 16% 24% 15% <0.001
Short-acting insulin 37% 51% 36% <0.001
Intermediate-acting insulin 36% 48% 35% <0.001
Long-acting insulin 16% 25% 15% <0.001
Unknown type/inhaled insulin <1% <1% <1% 0.7
Note: Values for continuous variables given as mean ± standard deviation or median [Q1-Q3].
Abbreviations: DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease; HD, hemodialysis; PD, peritoneal dialysis; Q,
quartile.
Original Investigationand with use of rapid-, short-, intermediate-, and long-
acting insulin had a higher likelihood of experiencing
hypoglycemia-related hospitalization(s) (Table S2).
Conversely, patients of white race and with higher704serum albumin levels were less likely to experience
hypoglycemia-related hospitalization(s). These patterns
of association largely persisted in analyses adjusted for
additional covariates.AJKD Vol 72 | Iss 5 | November 2018
Original InvestigationAntidiabetic Medications and Hypoglycemia-
Related Hospitalization Risk
We examined a subcohort of 28,047 patients who were
prescribed 0 to 2 oral antidiabetic drugs with or without
insulin (Table S3). In case-mix analyses, patients who were
prescribed an increasing number of oral antidiabetic drugs
(without insulin) had an incrementally higher risk for
hypoglycemia-related hospitalization(s) (the reference
group comprised patients prescribed neither oral antidia-
betic drugs nor insulin; Table 2). Using the same reference
group, we also observed that patients prescribed insulin
had higher risk for hypoglycemia-related hospitaliza-
tion(s), with even higher risk among those concomitantly
prescribed 1 or 2 oral antidiabetic drugs. This pattern of
findings persisted in analyses adjusted for expanded case-
mix and expanded case-mix plus laboratory covariates.
Among patients from this subcohort, we also examined
27,389 patients receiving the 12 most commonly pre-
scribed antidiabetic medication regimens (Table 2).
Compared with patients who were prescribed neither oralTable 2. Antidiabetic Medication Regimens Associated With Hypo
Prelude Period
Minimally
Adjusted
Case
Adjus
Medication combinations (n = 28,047a)
No antidiabetic drugs + no insulin 1.00 (reference) 1.00
No insulin + 1 antidiabetic drug 1.66 (1.38-2.00)b 1.68
No insulin + 2 antidiabetic drugs 2.42 (1.99-2.96)b 2.47
Insulin only 2.35 (2.02-2.74)b 2.39
Insulin + 1 antidiabetic drug 2.87 (2.45-3.35)b 2.91
Insulin + 2 antidiabetic drugs 2.70 (2.27-3.21)b 2.77
Most common medication patterns (n = 27,389c)
No insulin
No antidiabetic drug + no insulin 1.00 (reference) 1.00
Sulfonylurea only 1.81 (1.49-2.19)b 1.82
Thiazolidinedione only 1.05 (0.52-2.15) 1.06
Metformin 0.98 (0.52-1.86) 1.04
Sulfonylurea + thiazolidinedione 2.17 (1.62-2.90)b 2.18
Sulfonylurea + metformin 2.70 (2.09-3.50)b 2.79
Insulin
Insulin only 2.36 (2.02-2.74)b 2.39
Sulfonylurea + insulin 2.76 (2.30-3.32)b 2.78
Thiazolidinedione + insulin 2.76 (2.09-3.65)b 2.82
Metformin + insulin 3.36 (2.56-4.41)b 3.48
Sulfonylurea +
thiazolidinedione + insulin
2.47 (1.91-3.18)b 2.52
Sulfonylurea + metformin +
insulin
2.57 (2.04-3.24)b 2.66
Thiazolidinedione + metformin +
insulin
2.93 (1.86-4.59)b 3.08
Note: Values shown are odds ratio (95% conﬁdence interval). Minimally adjusted m
mix–adjusted model adjusted for covariates in the minimally adjusted model and ag
adjusted for covariates in the case-mix model and cause of end-stage kidney disease
disease, and Charlson Comorbidity Index score. Expanded case-mix + laboratory–adjus
A1c level, serum albumin level, estimated glomerular ﬁltration rate averaged over the p
therapy initiation.
aOnly included patients on treatment with 0, 1, or 2 oral antidiabetic drugs.
bStatistically signiﬁcant.
cOnly includes patients prescribed the 12 most common medication combinations.
AJKD Vol 72 | Iss 5 | November 2018antidiabetic drugs nor insulin, all antidiabetic medication
regimens were associated with higher risk for
hypoglycemia-related hospitalization except for thiazoli-
dinedione and metformin monotherapy.
Hypoglycemia-Related Hospitalization and
Mortality
Patients contributed a total of 57,673 patient-years of follow-
up, during which time 12,480 all-cause deaths occurred
(Table S4). Median at-risk time was 1.8 (Q1-Q3, 0.7-2.9)
years.We first examined the occurrence of any hypoglycemia-
related hospitalization over a more than 1- to 2-year prelude
period and post-ESRD mortality (Fig 1; Tables S5 and S6). In
case-mix models, the presence of any hypoglycemia-related
hospitalization was associated with higher mortality (refer-
ence group: those with absence of hypoglycemia-related
hospitalization). These findings were robust in analyses
restricted to patients with type 2 diabetes (Table S7) and
after incremental adjustment for expanded case-mix, labora-
tory, and medication covariates (Table S6), as well as eGFRglycemia-Related Hospitalizations in the More Than 1- to 2-Year
-Mix
ted
Expanded
Case-Mix Adjusted
Expanded Case-Mix +
Laboratory Adjusted
(reference) 1.00 (reference) 1.00 (reference)
(1.39-2.02)b 1.54 (1.27-1.86)b 1.50 (1.24-1.81)b
(2.02-3.01)b 2.25 (1.84-2.75)b 2.09 (1.71-2.57)b
(2.04-2.79)b 1.90 (1.61-2.23)b 1.70 (1.44-2.01)b
(2.48-3.42)b 2.28 (1.93-2.69)b 1.98 (1.66-2.35)b
(2.32-3.31)b 2.20 (1.83-2.64)b 1.83 (1.52-2.22)b
(reference) 1.00 (reference) 1.00 (reference)
(1.49-2.21)b 1.64 (1.35-2.00)b 1.62 (1.33-1.97)b
(0.52-2.16) 0.99 (0.49-2.03) 0.97 (0.47-1.98)
(0.55-1.96) 1.06 (0.56-2.02) 0.96 (0.50-1.83)
(1.62-2.92)b 1.95 (1.45-2.63)b 1.87 (1.39-2.52)b
(2.16-3.61)b 2.60 (2.00-3.37)b 2.34 (1.80-3.04)b
(2.04-2.80)b 1.90 (1.62-2.24)b 1.70 (1.44-2.01)b
(2.31-3.35)b 2.19 (1.81-2.64)b 1.94 (1.59-2.36)b
(2.13-3.73)b 2.20 (1.65-2.92)b 1.93 (1.44-1.58)b
(2.64-4.59)b 2.74 (2.07-3.63)b 2.15 (1.61-2.87)b
(1.95-3.25)b 1.98 (1.53-2.57)b 1.74 (1.33-2.27)b
(2.10-3.36)b 2.14 (1.68-2.72)b 1.71 (1.34-2.19)b
(1.95-4.85)b 2.49 (1.57-3.94)b 1.95 (1.22-3.11)b
odel adjusted for patient’s calendar quarter of dialysis therapy initiation. Case-
e at dialysis therapy initiation, sex, race, and ethnicity. Expanded case-mix model
, initial dialysis modality, residential region, congestive heart failure, cerebrovascular
ted model adjusted for covariates in the expanded case-mix model and hemoglobin
relude period, and last estimated glomerular ﬁltration rate obtained before dialysis
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Figure 1. Association between presence of hypoglycemia-
related hospitalization across various prelude periods and
mortality (reference group: absence of hypoglycemia-related hos-
pitalization). Minimally adjustedmodel adjusted for patient’s calen-
dar quarter of dialysis therapy initiation. Case-mix–adjusted model
adjusted for covariates in the minimally adjusted model and age at
dialysis therapy initiation, sex, race, and ethnicity. Expanded case-
mixmodel adjusted for covariates in the case-mixmodel and cause
of end-stage kidney disease, initial dialysis modality, residential re-
gion, congestive heart failure, cerebrovascular disease, andCharl-
son Comorbidity Index score. Expanded case-mix + laboratory
(lab)–adjusted model adjusted for covariates in the expanded
case-mix model and hemoglobin A1c level, serum albumin level,
estimated glomerular ﬁltration rate averaged over the prelude
period, and last estimated glomerular ﬁltration rate obtained
before dialysis therapy initiation. Expanded case-mix +
laboratory + medication–adjusted model adjusted for covariates
in the expanded case-mix + laboratory test model and insulin
and oral antidiabetic drugs. Abbreviation: CI, conﬁdence interval.
Original Investigationslope, number of oral antidiabetic drugs, and insulin type
used (Table S8). Similar findings were also observed in
sensitivity analyses examining any hypoglycemia-related
hospitalization over more than 6- to 12-month and more
than 2- to 5-year prelude periods (Fig 1; Tables S5 and S6).
In case-mix analyses, an increasing frequency of
hypoglycemia-related hospitalizations over the more than
1- to 2-year prelude period was also associated with incre-
mentally higher death risk (reference group: no
hypoglycemia-related hospitalizations; Fig 2; Tables S5 and
S9). Findings were robust in analyses restricted to patients
with type 2 diabetes (Table S7), and similar trends were
observed after incremental adjustment for expanded case-
mix, laboratory, medication, eGFR slope, number of oral
antidiabetic drugs, and insulin type covariates (Tables S8
and S9). When frequency of hypoglycemia-related hospi-
talizations was examined across more than 6- to 12-month
and more than 2- to 5-year prelude intervals, a similar
pattern of findings was observed (Fig 2; Tables S5 and S9).706Hypoglycemia-Related Hospitalization and
Mortality Across Subgroups
We also examined the association between occurrence of
any hypoglycemia-related hospitalization(s) over the more
than 1- to 2-year prelude period and mortality across
clinically relevant subgroups (Fig S2; Table S10). In case-
mix analyses, we observed effect modification of the
hypoglycemia-mortality association across subgroups of
age, race, and insulin use: P values for interactions
were <0.001, 0.04, and 0.05, respectively. We observed
stronger associations between hypoglycemia-related hos-
pitalization(s) and mortality among patients younger than
65 versus 65 years and older, nonwhite versus white race,
and insulin users versus nonusers.Discussion
In a large national incident ESRD cohort of US veterans
with diabetes, w6% of patients experienced a
hypoglycemia-related hospitalization within 2 years before
transitioning to dialysis therapy. We observed a dose-
dependent relationship between increasing frequency of
hypoglycemia-related hospitalizations and incrementally
higher mortality after transitioning to dialysis therapy,
such that experiencing 3 or more events in the pre-ESRD
prelude period was associated with 2-fold higher post-
ESRD death risk.
Increasing evidence suggests that hypoglycemia is a
frequent occurrence in diabetic patients with NDD-CKD,
with adverse implications on survival.21-23,41 In a second-
ary analysis of the ACCORD (Action to Control Cardiovas-
cular Risk in Diabetes) trial stratified by kidney function,
hypoglycemia rates were nearly 2-fold higher in patients
with mild to moderate CKD (stages 1-3 CKD) versus normal
kidney function.23 Although the association between hy-
poglycemia and mortality was not directly examined,
intensive glucose lowering versus standard therapy was
associated with 31% and 41% higher risk for all-cause and
cardiovascular death, respectively, in those with CKD, but
not in those without CKD. In another study of 8,767 type 2
diabetic patients from the Hong Kong Diabetes Registry,
hypoglycemia-related hospitalizations and CKD were each
independently associated with higher mortality, and pa-
tients with both hypoglycemia and CKD had nearly 4-fold
higher death risk compared with those with neither risk
factor.22 A large population-based study of 243,222 veter-
ans showed that the incidence of hypoglycemia ascertained
by blood glucose level in the ambulatory and inpatient
setting was higher in patients with versus without CKD.21
Moreover, there was a graded association between severity
of hypoglycemia and short-term (ie, 1-day) mortality that
was stronger among patients without versus with CKD.
However, inference from these findings was limited by the
lack of medication data and noncapture of hypoglycemia
events occurring outside the ambulatory and inpatient
setting. Furthermore, although these studies, which exclu-
sively focused on patients withNDD-CKD, inform the short-AJKD Vol 72 | Iss 5 | November 2018
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Figure 2. Association between frequency of hypoglycemia-
related hospitalizations across various prelude periods and
mortality (reference group: zero hypoglycemic hospitalizations).
Analyses adjusted for case-mix covariates, which include pa-
tient’s calendar quarter of dialysis therapy initiation, age at
dialysis therapy initiation, sex, race, and ethnicity. Abbreviation:
CI, conﬁdence interval.
Original Investigationterm complications of low glycemic status, little is known
about the long-term sequelae of hypoglycemia and partic-
ularly the long-term complications of repeated pre-ESRD
hypoglycemia episodes over time among patients with
CKD who survive to maintenance dialysis therapy. Hence,
our study provides insight into the long-term impact of
hypoglycemia events requiring medical attention during
later stages of CKD on postdialysis mortality risk of incident
patients with ESRD.
Given their disproportionate representation in the
broader CKD population and their heightened death risk
compared with nondiabetic counterparts,2 diabetic patients
with NDD-CKD progressing tomaintenance dialysis therapy
are a critical target for determining risk factors contributing
to this precarious postdialysis period. There are several
pathways by which hypoglycemia may lead to short-term
complications as observed in the mentioned studies. First,
glucose is a critical source of fuel for the central nervous
system,14,42 and hypoglycemia may directly lead to death
due to encephalopathy, seizures, and coma, as well as
indirectly by dizziness, disequilibrium, gait abnormalities,
and subsequent falls. Second, by causing an abrupt increase
in adrenergic activity, hypoglycemia may also precipitate
coronary ischemia, ventricular arrhythmias, and sudden
cardiac death.43 With respect to long-term sequelae,
recurrent hypoglycemia has been reported to diminish
autonomic nervous system responses (eg, cardiac vagal
baroflex sensitivity),42,44 further exacerbating cardiovas-
cular risk over time. It has been hypothesized that increased
frequency of hypoglycemia may explain the higher risk for
adverse cardiovascular outcomes observed in studies of
intensive glycemic control,10,12 which may be the pathway
by which pre-ESRD hypoglycemia events contributed toAJKD Vol 72 | Iss 5 | November 2018post-ESRD mortality in the present study. It is also possible
that coexisting factors increasing hypoglycemia suscepti-
bility (ie, protein-energy wasting, decreased kidney
function leading to impaired gluconeogenesis, and
uremia5) may contribute to mortality in this population.
Future studies examining specific mechanisms by which
hypoglycemia contributes to higher mortality specifically
in diabetic patients with CKD are needed.
Another novel contribution of our study was the ex-
amination of antidiabetic medication patterns as a modi-
fiable risk factor for hypoglycemia-related hospitalizations
in the pre-ESRD period. Although we observed a graded
association between number of prescribed oral antidiabetic
drugs and risk for hypoglycemia, prescription of insulin
alone had a similar magnitude of risk as compared to
prescription of 2 oral antidiabetic drugs, and the associa-
tion between hypoglycemia-related hospitalization(s) and
mortality risk was stronger in insulin versus non–insulin
users in subgroup analyses. Examination of the 12 most
commonly prescribed antidiabetic medication patterns by
drug class showed that compared to no receipt of oral
antidiabetic drugs or insulin, regimens that included sul-
fonylureas and/or insulin were associated with heightened
risk for hypoglycemia, whereas thiazolidinedione and
metformin monotherapy did not demonstrate higher risk.
Although these collective data suggest that certain oral
antidiabetic drugs may carry lower risk for hypoglycemia
versus other antidiabetic agents, these findings should be
tempered by the potential toxicities associated with met-
formin (metformin-associated lactic acidosis45-50) and
thiazolidinediones (fluid retention, osteoporosis, and
bladder cancer51-53) and US regulatory bodies’ recom-
mendations against the prescription of metformin among
patients with eGFRs < 30 mL/min/1.73 m2.54 Further
studies are needed to determine the net safety and effec-
tiveness of specific antidiabetic therapies in CKD.
The strengths of our study include its examination of a
large nationally representative cohort of incident patients
with ESRD with both pre- and post-ESRD information;
comprehensive availability of comorbidity, medication,
and laboratory data; and reduced confounding by differ-
ential health care access and nonuniform medical treat-
ment by receiving care within the VA system.
However, several limitations of our study bear mention.
First, we defined hypoglycemia events using hospitalization
records, likely capturing moderate to severe events and
potentially excluding mild episodes that did not require
medical attention. Hence, the frequency of events observed
may be an underestimation given reliance on ICD-9 codes
for ascertainment and potential noninclusion of patients
who died immediately after the hypoglycemia event before
initiating maintenance dialysis therapy. However, we
elected to use the former approach given the risk for
ascertainment bias that may be introduced by reliance
on blood glucose measurements (ie, noncapture of
hypoglycemia detected using capillary blood glucose
measurement at home). Second, our analyses examined707
Original Investigationprevalent antidiabetic medication use, which does not
account for patients who may have ceased medication use
due to adverse events or death, and prescription data may
not reflect actual intake of medications. Third, our exami-
nation of post-ESRD mortality does not assess the rela-
tionship between hypoglycemia and short-term death, and
our analyses did not include those who maintained stable
kidney function, experienced death, or underwent kidney
transplantation before dialysis therapy initiation or those
who declined dialysis therapy, who may be inherently
different from those who progressed to dialysis therapy.
However, because prior data have confirmed an association
between hypoglycemia events and immediate mortality risk
in CKD, our intention was to specifically examine the long-
term impact of pre-ESRD hypoglycemia on post-ESRD
mortality. Fourth, granular examination of patients’ clin-
ical characteristics showed that eGFRs at dialysis therapy
initiation tended to be higher among patients with
increasing frequency of hypoglycemia. Because higher
eGFRs may be a proxy of PEW and reduced muscle mass,
hypervolemia resulting in creatinine dilution, and/or
providers’ inclination toward earlier dialysis therapy initi-
ation among unstable patients, it is possible that underlying
ill health among patients with hypoglycemia may have
contributed to their heightened mortality risk. Although
multivariable analyses adjusted for proxies of protein-
energy wasting (serum albumin), fluid overload (CHF),
and comorbid condition burden (CCI score), we cannot
exclude the possibility of residual confounding by nutri-
tional status, hypervolemia, and illness. Fifth, given that our
analyses were restricted to veterans who are largely male,
with greater comorbid condition burden and lower socio-
economic status, our findings may have limited external
validity to distinct study populations, and the observed
hypoglycemia-mortality associations may be generalizable
only to patients with CKD who experienced hypoglycemia
in the more than 1 to 2 years prelude period before dialysis
therapy initiation as our primary exposure window. Last,
our findings do not indicate a causal association between
hypoglycemia-related hospitalization(s) and mortality.
In conclusion, we observed that hypoglycemia-related
hospitalization(s) during the pre-ESRD prelude period
were associated with higher post-ESRD mortality among
diabetic incident patients with ESRD, and this risk was
incrementally stronger with increasing frequency of hy-
poglycemia. Further studies are needed of management
strategies that prevent hypoglycemia episodes among
diabetic patients with NDD-CKD transitioning to dialysis
therapy to evaluate whether reducing such episodes re-
duces the exceedingly high death rate in ESRD.Supplementary Material
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